{"organizations": [], "uuid": "8680fdf9834beedbf1bd55a4cd7557c35e398a9c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-merck-says-its-selumetinib-granted/brief-merck-says-its-selumetinib-granted-orphan-drug-designation-by-fda-for-neurofibromatosis-type-1-idUSASB0C5WB", "country": "US", "domain_rank": 408, "title": "BRIEF-Merck Says Its Selumetinib Granted Orphan Drug Designation By FDA For Neurofibromatosis Type 1", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-15T13:42:00.000+02:00", "replies_count": 0, "uuid": "8680fdf9834beedbf1bd55a4cd7557c35e398a9c"}, "author": "", "url": "https://www.reuters.com/article/brief-merck-says-its-selumetinib-granted/brief-merck-says-its-selumetinib-granted-orphan-drug-designation-by-fda-for-neurofibromatosis-type-1-idUSASB0C5WB", "ord_in_thread": 0, "title": "BRIEF-Merck Says Its Selumetinib Granted Orphan Drug Designation By FDA For Neurofibromatosis Type 1", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda for neurofibromatosis type", "sentiment": "negative"}, {"name": "reuters) - merck & co inc", "sentiment": "none"}, {"name": "fda", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "merck & co inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 43 AM / Updated 10 minutes ago BRIEF-Merck Says Its Selumetinib Granted Orphan Drug Designation By FDA For Neurofibromatosis Type 1 Reuters Staff Feb 15 (Reuters) - Merck & Co Inc: * SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR NEUROFIBROMATOSIS TYPE 1 * MERCK & CO INC - ‍FDA GRANTED ORPHAN DRUG DESIGNATION FOR SELUMETINIB, A MEK 1/2 INHIBITOR, FOR TREATMENT OF NEUROFIBROMATOSIS TYPE 1​ * MERCK & CO INC - PHASE II TRIAL RESULTS FOR SELUMETINIB ARE EXPECTED LATER IN 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-15T13:42:00.000+02:00", "crawled": "2018-02-15T13:58:31.043+02:00", "highlightTitle": ""}